Meeting Details

  • Date: 23rd June, 2026
  • Type: 53rd Annual General Meeting (AGM)
  • Mode: Held through Video Conferencing
  • Timing: Commenced at 09:30 am and concluded at 10:05 am

Summary of Proposed Resolutions

The following six items of business were transacted at the meeting:

  • 1. Approval and adoption of the Standalone Financial Statements as at 31st March, 2026, including the Audited Balance Sheet, the Statement of Profit and Loss for the year ended on that date, and the reports of the Board of Directors and Auditors thereon.
  • 2. Approval and adoption of the Consolidated Financial Statements as at 31st March, 2026, including the Audited Balance Sheet, the Statement of Profit and Loss for the year ended on that date, and the reports of the Auditors thereon.
  • 3. Confirmation of payment of an interim dividend of ₹29.00 per equity share (face value ₹5.00 each) and declaration of a final dividend of ₹9.00 per equity share (face value ₹5.00 each) for the financial year ended 31st March, 2026.
  • 4. To appoint a Director in place of Samir Mehta (DIN: 00061903), who retires by rotation and, being eligible, offered himself for re-appointment.
  • 5. Ratification of remuneration of cost auditors of the Company for the year 2026-27.
  • 6. Issuance of Equity Shares including Convertible Bonds / Debentures.

Voting Process

The business was transacted by Remote e-voting and e-voting at the meeting. The process was conducted as required under the Companies Act, 2013, SEBI Listing Regulations, and Ministry of Corporate Affairs General Circular no. 20 read with Circular nos. 14 & 17 of 2020 and 03 of 2025.

Voting Outcomes and Scrutinizer's Report

The disclosure states that the declaration of results of voting, along with the Scrutinizer's Report and detailed results of voting as required under Regulation 44(3) of the Listing Regulations, will be disclosed to the Stock Exchanges separately. This document does not contain the specific voting outcomes or scrutinizer's findings.

Compliance Confirmation

The proceedings were conducted in compliance with the applicable laws and regulations, including the Companies Act, 2013, and SEBI Listing Regulations.

Other Information

  • BSE Scrip Code: 500420
  • NSE Scrip Code: TORNTPHARM
  • Company Contact Email: investorservices@torrentpharma.com